25T7-NBOMe

25T7-NBOMe
Clinical data
Other names2C-T-7-NBOMe; NBOMe-2C-T-7; N-(2-Methoxybenzyl)-4-propylthio-2,5-dimethoxyphenethylamine
Drug classSerotonin 5-HT2 receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Legal status
Legal status
Identifiers
  • 2-(2,5-dimethoxy-4-propylsulfanylphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H29NO3S
Molar mass375.53 g·mol−1
3D model (JSmol)
  • CCCSC1=C(C=C(C(=C1)OC)CCNCC2=CC=CC=C2OC)OC
  • InChI=1S/C21H29NO3S/c1-5-12-26-21-14-19(24-3)16(13-20(21)25-4)10-11-22-15-17-8-6-7-9-18(17)23-2/h6-9,13-14,22H,5,10-12,15H2,1-4H3
  • Key:CPVMNHOHOSNFOP-UHFFFAOYSA-N

25T7-NBOMe, also known as 2C-T-7-NBOMe or NBOMe-2C-T-7 as well as N-(2-methoxybenzyl)-4-propylthio-2,5-dimethoxyphenethylamine, is a serotonergic psychedelic of the 25-NB (NBOMe) family. It is the NBOMe analogue of 2C-T-7. The compound has been sold as a designer drug.[2][3][4][5][6]

Use and effects

[edit]

The active dose range and route of 25T7-NBOMe do not appear to have been described.[7]

Interactions

[edit]
See also: Psychedelic drug § Interactions, and Trip killer § Serotonergic psychedelic antidotes

Pharmacology

[edit]

Pharmacodynamics

[edit]
25T7-NBOMe activities
Target Affinity (Ki, nM)
5-HT1A 1,800
5-HT1B 1,902
5-HT1D 2,176
5-HT1E ND
5-HT1F ND
5-HT2A 0.68–1.1 (Ki)
7.42–260 (EC50Tooltip half-maximal effective concentration)
41–173% (EmaxTooltip maximal efficacy)
5-HT2B 2.3 (Ki)
310 (EC50)
14% (Emax)
5-HT2C 6.4 (Ki)
19.1 (EC50)
95% (Emax)
5-HT3 ND
5-HT4 ND
5-HT5A ND
5-HT6 68.8
5-HT7 ND
α1A 340
α1B, α1D ND
α2A 360
α2B, α2C ND
β1–β3 ND
D1 4,100
D2 1,000
D3 1,400
D4, D5 ND
H1 1,200
H2–H4 ND
M1–M5 ND
I1 ND
σ1, σ2 ND
ORs ND
TAAR1Tooltip Trace amine-associated receptor 1 1,000 (Ki) (mouse)
88–90 (Ki) (rat)
2,100 (EC50) (mouse)
550 (EC50) (rat)
>10,000 (EC50) (human)
68% (Emax) (mouse)
52% (Emax) (rat)
SERTTooltip Serotonin transporter 3,200 (Ki)
17,000 (IC50Tooltip half-maximal inhibitory concentration)
ND (EC50)
NETTooltip Norepinephrine transporter 3,700 (Ki)
34,000 (IC50)
ND (EC50)
DATTooltip Dopamine transporter 4,800 (Ki)
55,000 (IC50)
ND (EC50)
Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified. Refs: [8][9][10][2][3][11]

25T7-NBOMe acts as a highly potent and selective agonist of the serotonin 5-HT2 receptors.[2] Its affinities and activities at a variety of other receptors and transporters have also been described.[2]

History

[edit]

25T7-NBOMe was first described in the scientific literature by 2012.[12]

See also

[edit]

References

[edit]
  1. ^ Anvisa (2023-07-24). "RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 804 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-07-25). Archived from the original on 2023-08-27. Retrieved 2023-08-27.
  2. ^ a b c d Rickli A, Luethi D, Reinisch J, Buchy D, Hoener MC, Liechti ME (December 2015). "Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs)" (PDF). Neuropharmacology. 99: 546–553. doi:10.1016/j.neuropharm.2015.08.034. PMID 26318099.
  3. ^ a b Pottie E, Poulie CB, Simon IA, Harpsøe K, D'Andrea L, Komarov IV, et al. (August 2023). "Structure-Activity Assessment and In-Depth Analysis of Biased Agonism in a Set of Phenylalkylamine 5-HT2A Receptor Agonists". ACS Chemical Neuroscience. 14 (15): 2727–2742. doi:10.1021/acschemneuro.3c00267. PMC 10401645. PMID 37474114.
  4. ^ Botch-Jones S, Foss J, Barajas D, Kero F, Young C, Weisenseel J (October 2016). "The detection of NBOMe designer drugs on blotter paper by high resolution time-of-flight mass spectrometry (TOFMS) with and without chromatography". Forensic Science International. 267: 89–95. doi:10.1016/j.forsciint.2016.08.008. PMID 27572638.
  5. ^ Grumann C, Auwärter V (February 2018). "Separation of positional isomers of nine 2-phenethylamine-derived designer drugs by liquid chromatography-tandem mass spectrometry". Drug Testing and Analysis. 10 (7): 1184–1191. doi:10.1002/dta.2371. PMID 29455470.
  6. ^ Fan SY, Zang CZ, Shih PH, Ko YC, Hsu YH, Lin MC, et al. (August 2021). "Simultaneous LC-MS/MS screening for multiple phenethylamine-type conventional drugs and new psychoactive substances in urine". Forensic Science International. 325: 110884. doi:10.1016/j.forsciint.2021.110884. PMID 34245937. S2CID 235791505.
  7. ^ Luethi D, Liechti ME (October 2018). "Monoamine Transporter and Receptor Interaction Profiles in Vitro Predict Reported Human Doses of Novel Psychoactive Stimulants and Psychedelics". Int J Neuropsychopharmacol. 21 (10): 926–931. doi:10.1093/ijnp/pyy047. PMC 6165951. PMID 29850881.
  8. ^ "Ki values for 25T7-NBOMe". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill. 15 July 2025. Retrieved 15 July 2025.
  9. ^ Hansen M (2010-12-16). Design and Synthesis of Selective Serotonin Receptor Agonists for Positron Emission Tomography Imaging of the Brain (Ph.D. thesis). University of Copenhagen. doi:10.13140/RG.2.2.33671.14245.
  10. ^ Hansen M, Phonekeo K, Paine JS, Leth-Petersen S, Begtrup M, Bräuner-Osborne H, et al. (March 2014). "Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists". ACS Chemical Neuroscience. 5 (3): 243–249. doi:10.1021/cn400216u. PMC 3963123. PMID 24397362.
  11. ^ Simmler LD, Buchy D, Chaboz S, Hoener MC, Liechti ME (April 2016). "In Vitro Characterization of Psychoactive Substances at Rat, Mouse, and Human Trace Amine-Associated Receptor 1" (PDF). J Pharmacol Exp Ther. 357 (1): 134–144. doi:10.1124/jpet.115.229765. PMID 26791601. Archived from the original (PDF) on 2025-05-09.
  12. ^ Casale JF, Hays PA (2012). "Characterization of eleven 2, 5-dimethoxy-N-(2-methoxybenzyl) phenethylamine (NBOMe) derivatives and differentiation from their 3-and 4-methoxybenzyl analogues—part I." (PDF). Microgram Journal. 9 (2): 84–109.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=25T7-NBOMe&oldid=1300730892"